|
DAY 1 |
|
(May 10) |
|
6:30 PM |
|
Conference Registration |
|
7:30 PM |
|
Welcome Dinner (Hotel check-in, networking and informal discussions) |
|
|
|
|
|
CONFERENCE SESSIONS |
||
|
|
|
|
|
DAY 2 |
|
(May 11) |
|
|
|
|
|
8:00 AM |
|
Breakfast |
|
|
|
|
|
8:50 AM |
|
Welcome and Opening Remarks John Lambris (on behalf of the Organizing Committee) |
|
|
||
|
SESSION I |
Structural insights - mechanisms of activation and regulation Chairs: Christine Gaboriaud, Brian Geisbrecht |
|
|
9:00 AM |
1 |
Unveiling the unique interaction mechanism of herpes simplex virus 2 glycoprotein C with C3b Juan Fontana Instituto Biofisika,CSIC-UPV/EHU, Spain |
|
9:20 AM |
2 |
Viral teachings on complement regulation Arvind Sahu Regional Centre for Biotechnology, India |
|
9:40 AM |
3 |
Activation of native C3 without proteolytic cleavage induced by phosphatidyl serine containing membranes Bo Nilsson Uppsala University |
|
10:00 AM |
4 |
Complement C1 proteases as possible new therapeutic targets in diseases Christine Gaboriaud Institut de Biologie Structurale, CEA, France |
|
10:20 AM |
5 |
Sex Chromosome Regulation of Complement System Activity: Evidence for Post-Transcriptional Control of C3 and C4 Levels William Barr Massachusetts Institute of Technology, USA |
|
|
|
|
|
10:35 AM |
|
Coffee Break and Poster Viewing |
|
|
|
|
|
SESSION II |
Therapeutic complement inhibitors: from bench to bedside Chairs: Anna Schubart Wellensiek, Daniel Ricklin |
|
|
11:15 AM |
6 |
Therapeutic complement modulation at the forefront of novel immunotherapies: Misconceptions, myths, and novel insights John D. Lambris University of Pennsylvania, USA |
|
11:35 AM |
7 |
Inhibiting the Complement Classical Pathway by Blocking Activation of the C1r Zymogen Brian Geisbrecht Kansas State University, USA |
|
11:55 AM |
8 |
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators Daniel Ricklin University of Basel, Switzerland |
|
12:15 AM |
9 |
Complement Alternative Pathway Inhibitors for Hemocompatibility of Nanoparticles in Multiple Animal Species Dmitri Simberg University of Colorado, USA |
|
12:35 PM |
10 |
The story of empasiprubart (ARGX-117), a long acting inhibitory C2 antibody, from bench to MMN patients Inge Van de Walle Argenx BV, Belgium |
|
12:50 PM |
11 |
Iptacopan (Fabhalta) for the treatment of complement-mediated diseases Anna Schubart Wellensiek Novartis, Switzerland |
|
13:10 PM |
12 |
Augmenting cytotoxicity of pathogen-specific antibodies that initiate complement activation independent of the classical pathway Wilhelm Schwaeble University of Cambridge, UK |
|
13:25 PM |
13 |
TBD Dimitrios Mastellos NCSR ‘Demokritos’, Greece |
|
|
|
|
|
13:40 PM |
|
Lunch and Informal Discussions |
|
|
||
|
7:30 PM |
|
Dinner and Informal Discussions |
|
|
|
|
|
DAY 3
|
(May 12) |
|
|
|
|
|
|
SESSION III |
Novel therapeutic concepts and mechanisms of inflammation Chairs: Anna Blom, George Hajishengallis |
|
|
9:00 AM |
14 |
Maladaptive trained immunity and chronic inflammation George Hajishengallis Penn Dental Medicine, USA |
|
9:20 AM |
15 |
Compstatins abolish pathogenic fibroblast function associated with inflammatory maladaptation of tissues Markus Hoffmann University of Lübeck, Germany |
|
9:40 AM |
16 |
Targeting Fibroblast-Derived C3: A Potential Therapeutic Strategy to Halt Chronic Inflammation in IBD Gianluca Matteoli KU Leuven, Belgium |
|
10:00 AM |
17 |
The different responsiveness of C3- and C5-deficient murine BM cells to oxidative stress explains why C3 deficiency, in contrast to C5 deficiency, correlates with better pharmacological mobilization and engraftment of hematopoietic stem cells Mariusz Ratajczak University of Louisville, USA |
|
10:20 AM |
18 |
Granzyme K-driven complement activation Michael Brenner Harvard University, USA |
|
10:40 AM |
19 |
Activated fibroblasts produce high levels of complement component 3 during intestinal inflammation Gaia Zanella, BoJun Ke, Donatella Cicia, Veronika Bosàkovà, Saeed Abdurahim, Sneha Santhosh, Victoria Gudino, Marc Moro, Azucena Salas, Bram Verstockt, Severine Vermeire, and Gianluca Matteoli KU Leuven, Belgium |
|
10:55 AM |
20 |
RNA profiling, protein expression and gene deletion studies in rheumatoid arthritis patient synovium and murine models identifies critical roles for activation pathway effector mechanisms as well as factor H (FH) and FH-related families in disease pathogenesis Michael Holers University of Colorado, USA |
|
11:15 AM |
21 |
Complement activation in the intensive care unit: Therapeutic approaches on the central hub? Markus Huber-Lang Ulm University, Germany |
|
|
|
|
|
11:35 AM |
|
Coffee Break and Poster Viewing |
|
|
|
|
|
|
||
|
SESSION IV |
Complement in hemolytic disease and metabolism Chairs: Lubka Roumenina, Benjamin King |
|
|
12:15 PM |
22 |
Complement therapeutics in acute respiratory distress syndrome (ARDS) beyond SARS-CoV-2: a clinical perspective Fabio Ciceri, Sara Mastaglio, Andrea Assanelli, Cecilia Garlanda, Antonio Maria Risitano, Annalisa Ruggeri IRCCS San Raffaele Scientific Institute, Italy |
|
12:35 PM |
23 |
Breakthrough hemolysis in PNH patients on C3 inhibition: a role for immune adherence Christoph Schmidt University of Ulm Medical Centre |
|
12:55 PM |
24 |
Complement in Sickle Cell Disease Lubka Roumenina Centre de Recherche des Cordeliers, Sorbonne University, France |
|
13:15 PM |
25 |
The involvement of complement system in immune mediated platelet clearance processes Susa Savukoski, Alina Dettner, John Lambris, Markus Huber-Lang and Marco Mannes Ulm University Medical Center, Germany |
|
13:30 PM |
26 |
Complement and Diabetes in rodent models: complement controls metabolism, and metabolism controls complement Benjamin King Lund University, Sweden |
|
|
|
|
|
13:50 PM |
Lunch and Informal Discussions |
|
|
|
|
|
|
7:30 PM |
Dinner and Informal Discussions |
|
|
|
|
|
|
DAY 4 |
|
(May 13) |
|
|
|
|
|
SESSION V |
Complement in cancer Immunity and immunotherapy Chairs: Elena Magrini, Ruben Pio |
|
|
9:00 AM |
27 |
Selective pressures driving altered complement protein expression in the tumour microenvironment Monica Olcina University of Oxford, UK |
|
9:20 AM |
28 |
Targeting complement in immunosuppressive tumor microenvironments Ruben Pio CIMA-University of Navarra, Spain |
|
9:40 AM |
29 |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC Elena Magrini Humanitas Clinical and Research Center, Italy |
|
10:00 AM |
30 |
Complement factor H is a novel ligand for the inducible T cell co-stimulator (ICOS) and promotes survival or regulatory T cells in the glioma microenvironment Anna Blom Lund University, Sweden |
|
10:20 AM |
31 |
A spatial and tissue digital landscape of triple negative breast cancer and complement pathways Shankar Subramaniam University of California San Diego, USA |
|
10:40 AM |
32 |
Integrated complementomics reveals myeloid-mediated pro-tumoral reprogramming of ccRCC cells through intracellular C3 Mikel Rezola Artero, Alaeddine Redissi, Lubka Roumenina, and Idris Boudhabhay Centre de Recherche des Cordeliers, France |
|
|
|
|
|
10:55 AM |
|
Coffee Break and Poster Viewing |
|
|
|
|
|
SESSION VI |
Complement in ocular inflammation: genetic drivers and mechanistic insights Chairs: Majlinda Lako, Kip Connor |
|
|
11:40 AM |
33 |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven Gregory Hageman University of Utah - John A. Moran Eye Center, USA |
|
12:00 PM |
34 |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function Majlinda Lako Newcastle University, UK |
|
12:20 PM |
35 |
Refinement of associations between age-related macular degeneration and regulators of complement activation for discovery and improved translation Moussa Zouace, Chris Pappas, Burt Richards, and Gregory Hageman University of Utah, USA |
|
12:35 PM |
36 |
The C1q and gC1qR proteins as therapeutic targets in cancer Berhane Ghebrehiwet Stony Brook University, USA |
|
12:55 PM |
|
Flash Poster session A (20 min) |
|
13:15 PM |
Lunch and Informal Discussions |
|
|
15:00 PM |
|
Archaeological Tour to Knossos and Museum |
|
7:30 PM |
Dinner and Informal Discussions |
|
|
|
|
|
|
DAY 5 |
(May 14) |
|
|
SESSION VII |
Targeting Complement in kidney and infectious diseases Chairs: Elena Goicoechea de Jorge, Tom E Mollnes |
|
|
9:00 AM |
37 |
Complement dysregulation behind the scenes in ANCA-associated vasculitis Elena Goicoechea de Jorge Center for Biological Research Margarita Salas, Spain |
|
9:20 AM |
38 |
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors Matteo Stravalaci Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Italy |
|
9:40 AM |
39 |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury Gábor Pál Eötvös Loránd University and EvolVeritas Biotechnology, Hungary |
|
10:00 AM |
40 |
Real-world evidence for efficacy and safety of Iptacopan and Pegcetacoplan in patients with primary membranoproliferative glomerulonephritis (MPGN) Luca Antonucci, Giulia Bassanese, Maddalena Marasà, Federica Maritati, Luis Fernando Quintana Porras, Federico Alberici, Anne-Els van de Logt, Franz Schaefer, and Marina Vivarelli Bambino Gesù Children's Hospital IRCCS and University of Rome Tor Vergata, Italy |
|
10:15 AM |
41 |
Humoral Innate Immunity and Acute Phase Proteins in COVID-19 Cecilia Garlanda Istituto Clinico Humanitas and Humanitas University, Italy |
|
|
|
|
|
10:35 AM |
|
Coffee Break and Poster Viewing |
|
|
|
|
|
SESSION VIII |
Complement: driver of neuroinflammation in neurodegenerative diseases Chairs: Andrea Tenner, Wioleta Zelek |
|
|
11:15 AM |
42 |
Knowing the Enemy: Selectively targeting complement to treat Alzheimer disease and related dementias Andrea J. Tenner University of California at Irvine, USA |
|
11:35 AM |
43 |
Targeting complement in brain diseases B. Paul Morgan Cardiff University, UK |
|
11:55 AM |
44 |
Mapping complement expression in the brain: implications for neurodegenerative disease therapeutics Matthew Bright, Van Dien Nguyen, B. Paul Morgan, and Wioleta Zelek Cardiff University, UK |
|
12:15 PM |
45 |
A pathogenic role of C5aR2 activation in Amyotrophic Lateral Sclerosis John Lee, Jenny Fung, Alana Julianisya, Austin Read, and Trent Woodruff The University of Queensland, Australia |
|
12:35 PM |
46 |
Complement Activity in Emboli Retrieved During Thrombectomy for Ischemic Stroke E. Sander Connolly Columbia University, USA |
|
12:55 PM |
47 |
Targeting C5a Inflammation in ALS: Ex Vivo Findings from PMX205 Phase Ib Trial Jenny Fung, John Lee, and Trent Woodruff University of Queensland, Australia |
|
13:10 PM |
|
Flash poster session- B (up to 20 min) |
|
13:30 PM |
|
Closing remarks Lubka Roumenina and Dimitris Mastellos (On behalf of the organizing committee) |
|
|
|
|
|
13:35 PM |
|
Lunch and Informal Discussions |
|
|
|
|
|
8:00 PM |
Farewell dinner |
|
|
|
|
|
|
DAY 6 |
(May 15) |
|
|
|
Departure day |
|
|
|
|
|
|
POSTERS
The conference will include 1-2 live poster sessions during which registered presenters will be able to give a 3-min ‘flash’ poster talk highlighting the main findings of their study.
1. Contribution of complement activating anti-PLA2R1 autoantibodies in membranous nephropathy. Marco Catalano, Sara Montagner, Elisabetta Traggiai, and Elion Hoxha. Novartis - Biomedical Research, Switzerland 2. A Novel Tool for Complement Activation Profiling in AAV Gene Therapy. Samuel Butler, Klaudia Kulak, Viktoria Kozma, Cecilia Klint, Camilla Nilsson, Selvi Celik, and Jordi Rodo. Svar Life Science, Sweden 3. A novel multiplex functional assay can be utilized to elucidate the mechanisms of the complement system. Lucia Iuzzolino, Christina Hanack, Pascal Deschatelets, and Martin Kolev. Apellis Pharmaceuticals Inc. USA 4. Design and Evaluation of Glycomimetics as Ficolin-1 Antagonists. Said Rabbani, Oliver Schwardt, Martin Smiesko, and Daniel Ricklin. Department of Pharmaceutical Sciences, University of Basel, Switzerland 5. In vitro efficacy of recombinant Factor H, CPV-104, to antagonize alternative pathway C3/C5 convertases stabilization by NeFs from patients with primary C3 glomerulopathy (C3G). Zahra Imanifard, Francesca Penati, Sofia Padoa, Paulina Dabrowska-Schlepp, Elena Bresin, Ariela Benigni, Giuseppe Remuzzi, Marina Noris, and Roberta Donadelli. Istituto di Ricerche Farmacologiche Mario Negri IRCCS 6. In vitro effect of FB inhibitor in patients with primary Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN). Rossella Piras, Zahra Imanifard, Anna Schubart, Elena Bresin, Ariela Benigni, Giuseppe Remuzzi, Marina Noris, and Roberta Donadelli. Istituto di Ricerche Farmacologiche Mario Negri IRCCS 7. Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS). Cedric Battaglino, Iryna Bodnaruk, Katarzyna Kasperkiewicz, Paula Czyszczoń, Beata Filip-Psurska, Kamil Malik, Mikael Skurnik, Maciej Cedzyński et al. Institute of Medical Biology, Polish Academy of Sciences, Poland. 8. Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activation. Anna Świerzko, Krzysztof Mikołajczyk, Anna Maciejewska, Dariusz Martynowski, Łukasz Sobała, Gabriela Gajek, Paweł Link-Lenczowski, Marcin Czerwiński, Jolanta Łukasiewicz, Maciej Cedzyński. Institute of Medical Biology, Polish Academy of Sciences, Poland. 9. Immunostimulatory tRNA-derived RNAs in the circulation of patients with tuberculosis infection. Justin Gumas, Takuya Kawamura, Megumi Shigematsu, and Yohei Kirino. 10. Cell-intrinsic complement in endothelium. Marina De Castro Deus, Idris Boudhabhay, and Lubka Roumenina. Sorbonne Université, France. 11. Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry. Burt Richards, Bert Veuskens, Chris Pappas, Jin Liu, Robert Anstadt, Marc Toso, Jennifer Mohler, Jill Hageman, Brandi Williams, Moussa Zouache, Richard Pouw, and Gregory Hageman. 12. Astrocyte-Derived Complement C3 Drives Metabolic Syndrome via C3a Receptor Activation in Hypothalamic Appetite-Regulating Neurons. Carolin Gragoll, Elias Rawish, Michael Schneider, Timo Rusack, Joerg Koehl, and Ingo Eitel. 13. Therapeutic Potential of the C3aR Antagonist JR14a in Heart Failure With Preserved Ejection Fraction (HFpEF). Elias Rawish, Carolin Gragoll, Michael Schneider, Timo Rusack, Joerg Koehl, and Ingo Eitel. 14. Unraveling the contribution of complement in the initial days post lung transplantation. Inge Van de Walle, Karen De winter, Laura Bracke, Tim Delahaye, Rene Novysedlak, Jan Van Slambrouck, Annalisa Barbarossa, Xin Jin, Pheline Kortleven, Janne Kaes, Hanne Beeckmans, Sandra Claes Claes, Dominique Schols, Ariella Van de Sompel, Erik Hack, Saskia Bos, Robin Vos, Bart Vanaudenaerde, and Laurens Ceulemans. 15. A case of a young C3G patient with a multifactorial genetic background, treated with pegcetacoplan. Luca Antonucci, Antonio Gargiulo, Andrea Cappoli, Carolina Giannini, Isabella Guzzo, Marina Noris, Francesco Emma, Marina Vivarelli. 16. Structural insights into IgM and complement activation. Junyu Xiao 17. Serum complement internalization is needed for UV-mediated nuclear bubbling cell death. Nan-Shan Chang, Cheng-Chang Tsai 18. Combined complement C3 and CD14 inhibition reduce live Escherichia coli-induced inflammation, but not platelet activation in the presence and absence of antibiotics Ole Brekke,Ingrid Joakimsen, Bård Karlsen, Åse Emblem, Kristin Pettersen, Renathe Grønli, Tom E.Mollnes. 19. Asymmetric dimethylarginine: a biomarker bridging coronary heart disease and metabolical associated steatotic liver disease. Munisakhon Makhkamova 20. Granzyme K Activates the Entire Complement Cascade
|
||
Text